[5-FU based chemoradiotherapy for unresectable locally advanced pancreatic cancer].
Twenty-one patients with unresectable locally advanced pancreatic cancer were evaluated in this retrospective analysis. They received extra-beam radiotherapy(50.4-54 Gy/28-30 fractions)with concurrent continuous infusion of 5-FU(250 mg/m(2)day)between December 1999 and April 2007. The radiation field included primary tumor and adjacent lymph nodes. Twenty patients(95%)completed chemoradiotherapy, although one patient quit radiotherapy due to vomiting. No lethal side effects were observed. The response rate was 10%. One of the patients judged to have stable disease underwent resection after maintenance chemotherapy. The median progression free survival and the median overall survival were 6.4 and 12 months, respectively. In eleven patients(52%), the initial sites of disease progression were local or peritoneum without liver metastases, suggesting systemic effects of this treatment. In conclusion, 5-FU based chemoradiotherapyis well tolerated and provides definite benefits against unresectable locally advanced pancreatic cancer.
Niki
Toshiharu
T
Dept. of Gastrointestinal and Hepatobiliary Oncology, Hyogo Cancer Center, Japan.
Soejima
Toshinori
T
Yoshikawa
Takurou
T
Yamamoto
Yoshinobu
Y
Fujii
Osamu
O
Ohta
Yousuke
Y
Tsuda
Masahiro
M
Horita
Kazutsugu
K
Tsujino
Kayoko
K
Hirohata
Shigeya
S
Fujino
Yasuhiro
Y
Nishisaki
Hogara
H
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018450:Disease Progression; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D015996:Survival Rate
D000970:Antineoplastic Agents; D005472:Fluorouracil